NCT05186571View on ClinicalTrials.gov

Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old

UnknownOBSERVATIONAL
Enrollment

350,000

Participants

Timeline

Start Date

December 1, 2021

Primary Completion Date

March 1, 2022

Study Completion Date

April 28, 2022

Conditions
MyopericarditisMyocarditisVaccination; ComplicationsCOVID-19 PandemicSARS-CoV2 Infection
Interventions
BIOLOGICAL

Pfizer-BioNTech mRNA COVID-19 vaccination

Vaccination in children 5-11 years of age

Trial Locations (1)

2100

RECRUITING

Copenhagen University Hospital, Rigshospitalet, Copenhagen

Sponsors

Collaborators (1)

Innovation Fund Denmark
All Listed Sponsors
collaborator

Innovation Fund Denmark

INDIV

collaborator

Ministry of Education, Denmark

OTHER_GOV

lead

Rigshospitalet, Denmark

OTHER

NCT05186571 - Myopericarditis After Messenger Ribonucleic Acid (mRNA) COVID-19 Vaccination in Children 5-11 Years Old | Biotech Hunter | Biotech Hunter